Skip to main content
. 2002 Feb 1;109(3):409–417. doi: 10.1172/JCI14364

Figure 4.

Figure 4

PSA velocities after vaccination with PSA RNA–transfected DCs. Pretherapy (pre slope) and post-treatment (post slope) serum PSA kinetics of study candidates vaccinated with PSA RNA–transfected DCs were calculated as described previously (13). A linear regression model was used to obtain estimates on the change of serum PSA over time, and the differences between pre- and post-therapy log slope estimates were computed for each patient. (a–c) The results on the serum PSA kinetics in all seven patients who were eligible for analysis before (pre) and after (post) vaccine therapy. In one of seven patients available for analysis (a), a decrease in the log slope PSA was calculated upon initiation of therapy. In five of the seven evaluable patients we could demonstrate a significant reduction of the log slope PSA (patient 3, 5, 7, 9, 10) (b), whereas one patient (patient 2) exhibited unchanged (c) PSA velocities after treatment with PSA RNA-pulsed DCs. (d) Pre- (white bars) and post-therapy (black bars) log slope PSA values for the entire group. Asterisk indicates statistically significant differences between the pre- and post-treatment slope.